# Digitoxin (Digitalis purpurea / Digitalis lanata)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/digitoxin-digitalis-purpurea-digitalis-lanata
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** Digitalis purpurea glycoside, Crystalline digitalis, Digitoxinum, 3β-[(2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-2,6-dideoxy-β-D-ribo-hexopyranosyl)oxy]-14-hydroxy-5β,14β-card-20(22)-enolide, Digitoxin CAS 71-63-6

## Overview

Digitoxin is a phytosteroidal cardiac glycoside that inhibits the Na+/K+-ATPase membrane pump in cardiac myocytes, increasing intracellular calcium and producing positive inotropic, negative chronotropic, and negative dromotropic effects on the heart. In clinical cardiology, it has demonstrated efficacy in improving myocardial contractility in heart failure and controlling ventricular rate in atrial fibrillation, with therapeutic plasma concentrations maintained between 10–30 ng/mL and a half-life of approximately 5–9 days due to hepatic rather than renal elimination.

## Health Benefits

- **Positive Inotropic Effect (Heart Failure)**: Digitoxin inhibits sarcolemmal Na+/K+-ATPase, raising intracellular Na+ and secondarily Ca²⁺ via the Na+/Ca²⁺ exchanger, increasing the force of myocardial contraction and improving cardiac output in systolic heart failure.
- **Negative Chronotropic Effect (Rate Control)**: By enhancing vagal tone and slowing sinoatrial node firing, digitoxin reduces resting heart rate and improves ventricular filling time, making it clinically useful for rate control in atrial fibrillation and flutter.
- **[Anti-Inflammatory](/ingredients/condition/inflammation) [Cardiovascular](/ingredients/condition/heart-health) Protection**: At nanomolar concentrations (3–30 nM), digitoxin inhibits NF-κB signaling at the TAK-1/IKK checkpoint, suppressing IL-1β-induced MCP-1 and VCAM-1 expression and reducing monocyte adhesion and migration in endothelial cells.
- **Vasoprotective and Endothelial Effects**: Digitoxin activates PI-3-kinase/Akt and Ca²⁺/calmodulin-dependent protein kinase II pathways, stimulating endothelial NO-synthase (eNOS) and increasing nitric oxide bioavailability, conferring vasodilatory and cytoprotective effects in vascular endothelium.
- **Antiviral [Immune Modulation](/ingredients/condition/immune-support)**: Preclinical evidence indicates digitoxin enhances virus-triggered type I interferon production by promoting TRAF3/TRAF6 ubiquitination and facilitating TAK1/TBK1 phosphorylation, augmenting innate antiviral immune responses.
- **Potential Anticancer Activity**: In vitro studies across multiple human cancer cell lines report digitoxin-induced cytotoxicity and apoptosis at sub-micromolar concentrations; proposed mechanisms include HIF-1α destabilization and NF-κB suppression, though clinical applicability is constrained by the narrow therapeutic index.
- **Antiapoptotic Endothelial Effects**: Digitoxin at 3–30 nM attenuates TNF-α-induced apoptosis in human umbilical vein endothelial cells (HUVECs) by activating Akt-survival signaling, suggesting a direct cytoprotective role in vascular tissue under inflammatory stress.

## Mechanism of Action

Digitoxin's primary mechanism is selective, high-affinity inhibition of the α-subunit of the Na+/K+-ATPase (sodium-potassium pump) on cardiomyocyte plasma membranes; this reduces outward Na+ transport, elevating intracellular Na+ concentration and secondarily driving Ca²⁺ influx through the Na+/Ca²⁺ exchanger (NCX), increasing sarcoplasmic reticulum Ca²⁺ loading and the force of systolic contraction. At the signaling level, digitoxin blocks the canonical NF-κB pathway by interfering with TAK-1 and IκB kinase (IKK) activation, thereby suppressing pro-[inflammatory](/ingredients/condition/inflammation) gene transcription including cytokines, adhesion molecules (VCAM-1, ICAM-1), and chemokines (MCP-1); it concurrently inhibits p44/42-MAPK (ERK1/2) phosphorylation, further dampening inflammatory amplification cascades. Simultaneously, digitoxin activates the PI-3-kinase/Akt survival pathway and stimulates Ca²⁺/calmodulin-dependent protein kinase II (CaMKII), which phosphorylates and activates endothelial NO-synthase (eNOS), increasing nitric oxide production and providing vasoprotection. Additional mechanistic actions include modulation of TRAF3 and TRAF6 ubiquitination states, which potentiates TBK1-driven interferon regulatory factor 3 (IRF3) activation and type I interferon (IFN-α/β) induction, contributing to antiviral and potentially [immunomodulatory](/ingredients/condition/immune-support) effects observed in preclinical models.

## Clinical Summary

Clinical use of digitoxin has been documented in European cardiology practice for decades, primarily for chronic heart failure with reduced ejection fraction and for ventricular rate control in chronic atrial fibrillation, with outcomes broadly analogous to digoxin based on mechanism and historical clinical experience rather than equivalently powered head-to-head RCTs. Its principal pharmacokinetic advantage over digoxin—hepatic rather than renal elimination with a half-life of 5–9 days—makes it theoretically preferable in patients with renal impairment, though this advantage is also a liability because toxicity, once established, is more prolonged and harder to reverse. Therapeutic drug monitoring targets a plasma concentration of 10–30 ng/mL (approximately 13–39 nM), and toxicity correlates with levels exceeding this range, with arrhythmia being the most serious adverse outcome. Overall confidence in digitoxin's clinical efficacy for heart failure is moderate based on mechanism-supported historical data and extrapolation from digoxin RCTs, but the absence of contemporary large-scale trials means evidence is insufficient to assign modern guideline-level recommendations specific to digitoxin.

## Nutritional Profile

Digitoxin is a pure pharmacologically active compound, not a nutritional ingredient, and possesses no meaningful macronutrient, micronutrient, vitamin, or mineral content relevant to dietary supplementation. Its molecular structure is that of a steroidal cardiac glycoside (molecular weight 764.95 g/mol) composed of a digitoxigenin aglycone (a cardenolide steroid nucleus with a butenolide lactone at C-17) linked to three digitoxose sugar residues; the sugar moieties influence pharmacokinetic properties rather than nutritional value. Oral bioavailability is high, estimated at 90–100%, owing to efficient gastrointestinal absorption; the compound is 90–97% bound to plasma proteins (primarily albumin), with a volume of distribution of approximately 0.5–0.7 L/kg, and undergoes enterohepatic recirculation contributing to its prolonged half-life. Hepatic [metabolism](/ingredients/condition/weight-management) via CYP3A4 produces digitoxigenin, bisdigitoxoside, and minor quantities of digoxin (approximately 2% conversion), with biliary excretion as the predominant elimination route; no dietary interactions affecting bioavailability are well-characterized beyond the general CYP3A4 interaction network.

## Dosage & Preparation

- **Pharmaceutical Oral Tablets**: Standard digitoxin tablets are available in 0.05 mg (50 mcg) and 0.1 mg (100 mcg) strengths; typical adult maintenance doses range from 0.05–0.2 mg/day, individualized by serum level monitoring.
- **Loading (Digitalizing) Dose**: Oral digitalization may use 0.6 mg initially, followed by 0.4 mg and then 0.2 mg at 6–8 hour intervals, with transition to maintenance thereafter; intravenous loading is used in acute settings under hospital supervision only.
- **Therapeutic Drug Monitoring**: Target serum digitoxin concentration is 10–30 ng/mL; levels should be measured at steady state (approximately 3–4 weeks after dose change given the long half-life of 5–9 days).
- **Renal Impairment Adjustment**: Unlike digoxin, dose adjustment for renal impairment is less critical because digitoxin undergoes primarily hepatic [metabolism](/ingredients/condition/weight-management) and biliary excretion; however, dose reduction is required in significant hepatic dysfunction.
- **Historical Foxglove Preparations**: Traditional preparations included dried powdered Digitalis leaf in doses of 60–200 mg, or infusions of foxglove leaves; these are obsolete, imprecise, and considered dangerous due to unpredictable glycoside content and lack of standardization.
- **No Supplemental/OTC Forms**: Digitoxin is not available as a dietary supplement or nutraceutical in any jurisdiction; all commercially available forms are prescription-only pharmaceutical preparations subject to regulatory oversight.
- **Timing**: Oral tablets are typically administered once daily with or without food; consistent timing improves steady-state predictability given the long half-life.

## Safety & Drug Interactions

Digitoxin carries a narrow therapeutic index—the toxic dose is only modestly above the therapeutic dose—and overdose produces potentially life-threatening cardiac arrhythmias including ventricular tachycardia, ventricular fibrillation, complete heart block, and sinus bradycardia through excessive Na+/K+-ATPase inhibition; non-cardiac toxicity includes nausea, vomiting, visual disturbances (xanthopsia, blurred vision), and neurological symptoms (confusion, fatigue). Significant drug interactions arise from CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, calcium channel blockers) that reduce digitoxin clearance and raise plasma levels toward toxicity, while CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort) accelerate [metabolism](/ingredients/condition/weight-management) and may cause subtherapeutic levels; P-glycoprotein inhibitors (amiodarone, verapamil) also reduce renal and biliary efflux, raising exposure. Hypokalemia and hypomagnesemia critically potentiate digitoxin toxicity by sensitizing Na+/K+-ATPase to glycoside inhibition, making concurrent diuretic use without electrolyte monitoring particularly hazardous; calcium administration in digitoxin-toxic patients can precipitate fatal arrhythmias and is contraindicated. Digitoxin is contraindicated in ventricular fibrillation, hypertrophic obstructive cardiomyopathy (where increased contractility is harmful), and Wolf-Parkinson-White syndrome with atrial fibrillation; it is classified FDA Pregnancy Category C with insufficient safety data in lactation, and use in pregnancy or breastfeeding requires specialist risk-benefit assessment.

## Scientific Research

The clinical evidence base for digitoxin is older and substantially thinner than that for its close analog digoxin; no large, modern randomized controlled trials (RCTs) with digitoxin as the primary intervention have been published with the methodological rigor of the DIG trial (digoxin, n=6,800). Most clinical pharmacology data derive from pharmacokinetic studies, case series, and observational reports from the mid-20th century establishing its therapeutic plasma range and elimination profile. Preclinical mechanistic evidence is more robust: in vitro studies in human endothelial cell models (HUVECs) have rigorously characterized [NF-κB](/ingredients/condition/inflammation) inhibition, eNOS activation, and antiapoptotic signaling at nanomolar concentrations (3–30 nM), with reproducible quantitative outcomes, but these do not constitute clinical efficacy evidence. Anticancer potential has been demonstrated across multiple cancer cell lines in cell culture and some rodent xenograft models, yet no completed Phase II or Phase III oncology trials with digitoxin have yielded published efficacy data, and the narrow therapeutic index remains the primary translational barrier.

## Historical & Cultural Context

The medicinal use of foxglove (Digitalis purpurea) was formally introduced to Western medicine by English physician William Withering in his landmark 1785 monograph 'An Account of the Foxglove and Some of Its Medical Uses,' documenting 163 clinical cases and describing the plant's utility in dropsy (edema secondary to heart failure), though folk healers in the English Midlands had used foxglove empirically for generations prior. Traditional preparations involved dried, powdered foxglove leaves administered as boluses or infusions, with highly variable potency and a significant risk of toxicity, reflecting the absence of any standardization for individual glycoside content. The isolation of pure digitoxin as a discrete chemical entity was achieved by European chemists in the late 19th and early 20th centuries, with its full steroidal aglycone structure elucidated by Adolf Windaus and colleagues, leading to pharmaceutical standardization that replaced botanical preparations. Digitoxin was widely prescribed across Europe, particularly in Germany and the Nordic countries, well into the late 20th century and retains some use in European cardiology today, even as digoxin became predominant in Anglo-American practice due to its shorter half-life and renal elimination profile.

## Synergistic Combinations

In historical and contemporary cardiology practice, digitoxin is often combined with diuretics (particularly loop diuretics such as furosemide) to manage the fluid overload of congestive heart failure; however, this combination demands vigilant electrolyte monitoring because diuretic-induced hypokalemia markedly sensitizes the myocardium to digitoxin toxicity and can precipitate arrhythmias. Magnesium supplementation has been used adjunctively in digitoxin therapy to stabilize membrane potential and reduce the risk of glycoside-induced arrhythmias, as magnesium is a physiological cofactor for Na+/K+-ATPase function and its repletion partially antagonizes excessive pump inhibition. In experimental [anti-inflammatory](/ingredients/condition/inflammation) contexts, the NF-κB-inhibitory activity of digitoxin at low nanomolar concentrations has been conceptually compared to combination with other NF-κB modulators such as corticosteroids, but no clinical synergy protocols for digitoxin outside cardiac indications have been established or validated in human trials.

## Frequently Asked Questions

### What is digitoxin used for medically?

Digitoxin is a prescription cardiac glycoside used clinically to improve myocardial contractility in systolic heart failure and to control ventricular rate in atrial fibrillation and flutter by inhibiting the Na+/K+-ATPase pump in heart muscle cells. It is not approved as a dietary supplement and is used exclusively under physician supervision with therapeutic drug monitoring targeting plasma concentrations of 10–30 ng/mL.

### How is digitoxin different from digoxin?

The key pharmacokinetic difference is that digitoxin undergoes primarily hepatic metabolism and biliary excretion with a half-life of 5–9 days, whereas digoxin is renally eliminated with a shorter half-life of 36–48 hours; this makes digitoxin theoretically safer in patients with kidney disease but means toxicity is more prolonged and harder to reverse if it occurs. Both drugs share the same primary mechanism—Na+/K+-ATPase inhibition—and similar therapeutic indications, but digitoxin is more extensively protein-bound (90–97%) and has higher oral bioavailability (near 100% versus approximately 70–80% for digoxin tablets).

### What are the serious side effects and toxicity risks of digitoxin?

Digitoxin has a narrow therapeutic index, and toxicity can manifest as cardiac arrhythmias (including potentially fatal ventricular tachycardia or fibrillation and heart block), bradycardia, nausea, vomiting, and neurological symptoms such as visual disturbances (yellow-green halos, xanthopsia) and confusion. Hypokalemia dramatically increases toxicity risk, so concurrent diuretic use without electrolyte monitoring is particularly dangerous; serum digitoxin levels must be regularly measured to maintain the safe range of 10–30 ng/mL.

### Does digitoxin have anticancer properties?

Preclinical in vitro and animal studies have shown digitoxin induces apoptosis and cytotoxicity in multiple human cancer cell lines, with proposed mechanisms including NF-κB pathway suppression and HIF-1α destabilization, which could theoretically reduce tumor survival under hypoxic conditions. However, no completed Phase II or III clinical trials have established digitoxin as an effective anticancer agent in humans, and its narrow therapeutic index—where anti-tumor concentrations may overlap with cardiotoxic concentrations—remains the principal barrier to clinical translation.

### Can digitoxin be taken as a supplement or bought over the counter?

No—digitoxin is not available as a dietary supplement or over-the-counter product in any country; it is classified as a prescription-only pharmaceutical in all jurisdictions where it is approved, due to its narrow therapeutic index and serious toxicity potential. Any exposure to digitoxin or related glycosides outside of medically supervised pharmaceutical prescription, including through consumption of foxglove plant preparations, is considered dangerous and potentially lethal.

### What is the narrow therapeutic window of digitoxin and why is monitoring important?

Digitoxin has a very narrow margin between an effective therapeutic dose and a toxic dose, with therapeutic levels typically ranging from 10-35 ng/mL. This narrow window means that small variations in absorption, metabolism, or kidney function can quickly lead to overdose, making regular blood level monitoring and dose adjustments essential during treatment. Factors like age, liver disease, kidney impairment, and electrolyte imbalances (especially potassium and magnesium) significantly affect digitoxin levels and toxicity risk.

### How does digitoxin's long half-life affect dosing schedules and accumulation in the body?

Digitoxin has an extended half-life of 5-7 days, meaning it accumulates in body tissues over time and requires careful dosing to prevent dangerous buildup. Due to this long half-life, digitoxin is typically given once daily rather than multiple times per day, and steady-state levels may not be reached for 2-3 weeks after starting treatment. This slow accumulation pattern necessitates lower initial dosing and close clinical monitoring to avoid toxicity as the drug builds up in the system.

### What electrolyte imbalances increase the risk of digitoxin toxicity?

Low potassium (hypokalemia), low magnesium (hypomagnesemia), and high calcium (hypercalcemia) significantly increase digitoxin toxicity risk by enhancing the drug's cardiac effects and arrhythmogenic potential. Patients taking diuretics or other medications that deplete potassium are at particular risk and require careful electrolyte monitoring while on digitoxin. Maintaining adequate potassium and magnesium levels is a critical safety measure in digitoxin therapy, as even modest electrolyte depletion can precipitate serious cardiac arrhythmias.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*